west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "5-羟色胺再摄取抑制剂" 3 results
  • Effect of Paroxetine on Sleep Apneas in Sprague-Dawley Rats

    Objective To evaluate the effects of selective serotonin reuptake inhibitors ( SSRIs) on sleep apneas in Sprague-Dawley ( SD) rats. Methods Thirty adultmale SD rats were randomly divided into two groups ( 15 rats in each group) . The treatment group and the control group were injected intraperitoneally with paroxetine ( 10 mg· kg- 1 · d - 1 ) and sterile distilled water ( 2 mL· kg- 1 · d - 1) for 7 days respectively. Parameters about sleep apnea and sleep structure were measured before and after the treatment. Results In the treatment group, there was a significant reduction of apnea index ( AI) from ( 12. 4 ±3. 7)times /hour to ( 7. 4 ±2. 2) times/ hour ( P = 0. 000) . Both post sigh apnea index ( PSAI) and spontaneous apnea index ( SPAI) were decreased significantly ( P = 0. 000 and 0. 021 respectively) in non-rapid eye movement ( NREM) sleep, but not in REM sleep. REM sleep was reduced from 8. 6% to 8. 0% ( P =0. 013) and its latency was increased from ( 54. 1 ±48. 4) min to ( 110. 9 ±43. 4) min ( P = 0. 001) in the treatment group, as well as the sleep-onset latency [ from ( 20. 7 ±9. 1) min to ( 30. 0 ±15. 7) min, P =0. 038] . Conclusion Paroxetine can reduce sleep apneas in SD rats during NREMsleep. Its effects on sleep structure include reducing REM time, increasing REM latency and sleep-onset latency.

    Release date:2016-09-14 11:23 Export PDF Favorites Scan
  • 精神科门诊5-羟色胺再摄取抑制剂抗抑郁药物用药状况分析

    【摘要】 目的 分析5-羟色胺再摄取抑制剂抗抑郁药物门诊治疗用药状况。 方法 抽取2010年8月23-29日四川大学华西医院精神科门诊1周的处方,采用限定日剂量分析法,分析用药频度、用药费用及合理用药情况。 结果 1周门诊量3 625例,其中焦虑抑郁性障碍1 518例(41.88%);诊断抑郁症者最多,为926例(61.0%),其次为焦虑症273例(18.0%)、焦虑状态132例(8.7%)、强迫症93例(6.1%),其余患者分别诊断为惊恐障碍、轻度抑郁症、抑郁状态及抑郁症伴焦虑等。用药频度由高到低依次为舍曲林、帕罗西汀、氟西汀、氟伏沙明和西酞普兰。日治疗消费额度由高到低依次:舍曲林、帕罗西汀、西酞普兰、氟西汀和氟伏沙明。 结论 5-羟色胺再摄取抑制剂抗抑郁药物的门诊用药符合临床合理用药规律,遵循循证医学证据用药。

    Release date:2016-09-08 09:26 Export PDF Favorites Scan
  • Efficacy and Safety of Selective Serotonin Reuptake Inhibitors for Parkinson's Disease Patients with Depression: A Systematic Review

    ObjectiveTo systematically review the efficacy and safety of selective serotonin reuptake inhibitors (SSRIs) in the treatment of Parkinson's disease patients with depression. MethodsThe Cochrane Library (Issue 5, 2014), PubMed, EMbase, CNKI, VIP and WanFang Data databases were searched from inception to May 2014 for randomized controlled trials (RCTs) investigating the efficacy and safety of SSRIs for Parkinson's disease patients with depression. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data, and assessed the methodological quality of included studies. Then meta-analysis was performed using RevMan 5.2 software. ResultsA total of 12 RCTs were included. The results of meta-analysis showed that the efficacy of SSRIs was better than placebo (RR=2.18, 95%CI 1.60 to 2.97, P<0.000 01) and the dropouts rates of SSRIs were higher than placebo (OR=3.02, 95%CI 1.04 to 8.79, P=0.04). However, the incidence rate of adverse events between the SSRIs group and the placebo group was not statistically different. ConclusionCurrent evidence indicates that SSRIs are effective for the Parkinson's disease patients with depression. Because of the limitation of quantity and quality of included studies, large-scale multi-center RCTs are required to confirm these findings.

    Release date:2016-10-02 04:54 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content